Filing Flows › Neurocrine Biosciences (NBIX) › Q2 2026 › vs Q1 2026
Neurocrine Biosciences (NBIX) Q2 2026 vs Q1 2026 (quarter over quarter)
Neurocrine Biosciences's revenue rose $144M (+18%) from $814M in Q1 2026 to $959M in Q2 2026. The biggest changes: Net product sales +$143M (+18%); Collaboration revenues +$1.2M (+34%). Operating margin 15.8% against 23.7% (-7.9 pts).
Neurocrine Biosciences, Q2 2026: revenue $959M (+40% year over year), operating margin 15.8%, net earnings $144M, operating cash flow $136M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 15.8% | 23.7% | -7.9 pts |
| Net margin | 15.1% | 24.3% | -9.2 pts |
| Free cash flow margin | 13.4% | 16.8% | -3.4 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Net product sales | $954M | $811M | $143M | +18% |
| Collaboration revenues | $4.7M | $3.5M | $1.2M | +34% |
| Revenue | $959M | $814M | $144M | +18% |
| Other income, net | $10.7M | $53.4M | −$42.7M | -80% |
| Operating profit | $152M | $193M | −$41.9M | -22% |
| Costs & expenses | $808M | $621M | $186M | +30% |
| Pre-tax earnings | $162M | $247M | −$84.6M | -34% |
| Net earnings | $144M | $198M | −$53.5M | -27% |
| Income tax | $17.8M | $48.9M | −$31.1M | -64% |
| Depreciation & amortization | $24.8M | $7.3M | $17.5M | +240% |
| Share-based compensation | $65.0M | $57.2M | $7.8M | +14% |
| Working capital & other | $97.8M | $117M | −$18.8M | -16% |
| Operating cash flow | $136M | $146M | −$9.4M | -6% |
| Free cash flow (OCF − capex) | $129M | $137M | −$8.1M | -6% |
| Capital expenditures | $7.8M | $9.1M | −$1.3M | -14% |
Questions
How much did Neurocrine Biosciences's revenue grow quarter over quarter in Q2 2026?
Neurocrine Biosciences's revenue rose $144M (+18%) from $814M in Q1 2026 to $959M in Q2 2026.
What drove Neurocrine Biosciences's revenue change in Q2 2026?
Net product sales +$143M (+18%); Collaboration revenues +$1.2M (+34%).